Short interest for HUTCHMED (China) gives investors a sense of the degree to which investors are betting on the decline of HUTCHMED (China)'s stock. Short interest data is updated every two weeks.

HUTCHMED (China) Stock (NASDAQ:HCM), Short Interest Report

HUTCHMED (China)

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAOI

FUTU

MOMO

NUKK

TIGR

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday.

Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Intraday Update

ADTH

AIRE

ANNX

ATER

BGNE

BIRD

BTOG

CLOV

CMTL

DLTR

ECDA

EDUC

GXAI

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HRTX

Kintara Therapeutics, Inc. - Common Stock

KTRA

LICY

LUNA

MINM

MNMD

NAAS

NATR

NCNA

NMRA

PIII

PRTG

RXRX

SIGA

SKIN

SMMT

SURG

SWIN

VERI

VJET

Shares of  Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

AEVA

ATUS

BHIL

HUIZ

PIXY

TNON

ZCMD

Shares of  SurgePays, Inc.  (NASDAQ: SURG) fell sharply in today’s pre-market trading after the company reported worse-than-expected fourth-quarter financial results.

Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China) Ltd

HCM ACQUISITION CORP USD CL A ORD SHS

HCM ACQUISITION CORP USD UNITS CONSISTING ONE CL A ORD SH OF $0.0001 PAR VALUE &

HCM ACQUISITION CORP USD RED WTS

HEALTHIER CHOICES MGMT by Healthier Choices Management Corp.

Healthier Choices Management Corp

Holcim Ltd

Direxion Shares ETF Trust Direxion HCM Tactical Enhanced US ETF

Vital Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTLE#NYSE">VTLE</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.97 by 6.6 percent. This is a 59.11 percent decrease over earnings of $4.50 per share from the same period last year. The company reported quarterly sales of $482.339 million which beat the analyst consensus estimate of $462.672 million by 4.25 percent. This is a 45.06 percent increase over sales of $332.507 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

VTLE

Vital Energy Q1 2024 Adj EPS $1.84 Misses $1.97 Estimate, Sales $482.339M Beat $462.672M Estimate

WIIM

MKSI

MKS Instruments shares are trading higher after the company reported better-than-expected Q1 financial results.

STKL

SunOpta shares are trading higher after the company raised its FY24 revenue guidance.

CompoSecure, Inc. ("CompoSecure" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>), a leader in metal payment cards, security, and authentication solutions, today announced the commencement of an underwritten public offering (the "Offering") of 7,000,000 shares of the Company's Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), by certain shareholders of the Company (the "Selling Shareholders"). In connection with the Offering, the Selling Shareholders expect to grant the underwriters a 30-day option to purchase an additional 1,050,000 shares of Class A Common Stock. CompoSecure is not offering any shares of its Class A Common Stock in the Offering and will not receive any proceeds from the sale of shares of Class A Common Stock in the Offering. &nbsp;
J.P. Morgan, BofA Securities and TD Cowen are acting as joint book-running managers for the Offering.

Offerings

CMPO

CompoSecure Announces Launch Of Secondary Offering Of 7M Shares Of Class A Common Stock By Selling Shareholders

ZIMV

ZimVie shares are trading higher following Q1 earnings. The company also issued strong FY24 EPS guidance.

RXST

RxSight shares are trading lower after the company announced a $100 million proposed public offering of common stock.

Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) reported quarterly earnings of $1.34 per share. This is a 332.26 percent increase over earnings of $0.31 per share from the same period last year. The company reported $46.98 million in sales this quarter. This is a 35.49 percent increase over sales of $34.67 million the same period last year.

SEZL

Sezzle Q1 EPS $1.34 Up From $0.31 YoY, Sales $46.98M Up From $34.67M YoY

AZEK

Azek shares are trading lower. The company reported Q2 financial results.

NL Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NL#NYSE">NL</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.12 by 16.67 percent. This is a 200 percent increase over losses of $(0.14) per share from the same period last year. The company reported $38.00 million in sales this quarter. This is a 7.77 percent decrease over sales of $41.20 million the same period last year.

NL Industries Q1 EPS $0.14 Beats $0.12 Estimate, Sales $38.00M Down From $41.20M YoY

EQIX

Equinix shares are trading higher following Q1 earnings.

Luokung Technology Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/LKCO#NASDAQ">LKCO</a>) ("Luokung" or the "Company"), a leading spatial-temporal intelligent big data services company and provider of interactive location-based services ("LBS") and high-definition maps ("HD Maps") in China, today announced that on May 2, 2024, the Company received an additional 180 calendar day extension ("Second Compliance Grace Period") from Nasdaq's Listing Qualifications Department to meet Nasdaq's continuing listing requirements by maintaining a minimum bid price per share of $1.00 for a minimum of 10 consecutive trading days. The Company now has until October 28, 2024 &nbsp;to regain compliance.
Nasdaq's extension notice has no immediate effect on the continued listing status of the Company's ordinary shares on Nasdaq. If at any time before October 28, 2024 , the bid price of the Company's ordinary shares closes at or above $1.00 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules, and the matter will be closed.
The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A) on November 3, 2023, and was given until May 1, 2024 to regain compliance.

LKCO

Luokung Granted Extension To Meet Nasdaq Minimum Bid Price Requirement

Mativ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATV#NYSE">MATV</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.20 by 90 percent. This is a 92 percent decrease over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $500.20 million which beat the analyst consensus estimate of $492.00 million by 1.67 percent. This is a 26.33 percent decrease over sales of $679.00 million the same period last year.

MATV

Mativ Holdings Q1 Adj $0.02 Misses $0.20 Estimate, Sales $500.20M Beat $492.00M Estimate

Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 137.84 percent decrease over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $79.287 million which beat the analyst consensus estimate of $63.560 million by 24.74 percent. This is a 8.78 percent decrease over sales of $86.920 million the same period last year.

Intrepid Potash Q1 2024 Adj EPS $(0.14) Misses $(0.12) Estimate, Sales $79.287M Beat $63.560M Estimate

Biotech

General

CSTL

Castle Biosciences Announced Data From Study Further For Performance Of Its DecisionDx-UM

Weis Markets (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMK#NYSE">WMK</a>) reported quarterly earnings of $0.86 per share. This is a 10.42 percent decrease over earnings of $0.96 per share from the same period last year. The company reported $1.18 billion in sales this quarter. This is a 3.06 percent increase over sales of $1.15 billion the same period last year.

Weis Markets Q1 EPS $0.86 Down From $0.96 YoY, Sales $1.18B Up From $1.15B YoY

DiaMedica Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 30 percent increase over losses of $(0.20) per share from the same period last year.

DMAC

DiaMedica Therapeutics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate

Contracts

Arq Announces Supply Contract For Strategic Granular Activated Carbon Facility; North American Solutions Provider Of Water And Wastewater Treatment And PFAS Capture Technologies To Purchase Forecasted 5 Million Pounds Of GAC Product In 2025

FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 150 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $30.754 million which beat the analyst consensus estimate of $27.684 million by 11.09 percent. This is a 13.22 percent increase over sales of $27.162 million the same period last year.

FGI Industries Q1 2024 Adj EPS $(0.05) Misses $(0.03) Estimate, Sales $30.754M Beat $27.684M Estimate

SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.20) by 105 percent. The company reported quarterly sales of $1.400 million which beat the analyst consensus estimate of $303.000 thousand by 362.05 percent. This is a 23.89 percent increase over sales of $1.130 million the same period last year.

SCYX

SCYNEXIS Q1 2024 GAAP EPS $0.01 Beats $(0.20) Estimate, Sales $1.400M Beat $303.000K Estimate

Miller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) reported quarterly earnings of $1.47 per share. This is a 81.48 percent increase over earnings of $0.81 per share from the same period last year. The company reported $349.87 million in sales this quarter. This is a 23.95 percent increase over sales of $282.27 million the same period last year.

Miller Industries Q1 EPS $1.47 Up From $0.81 YoY, Sales $349.87M Up From $282.27M YoY

Hutchmed (China) Limited (HCM) has released an update. HUTCHMED has announced the advancement of its Phase II/III clinical trial for sovleplenib, a...

HUTCHMED Advances Sovleplenib Trial in China

Hutchmed (China) Limited (HCM) has released an update. HUTCHMED (China) Limited has announced that China's National Medical Products Administration...

HUTCHMED's Savolitinib sNDA Under Review in China

Hutchmed (China) Limited (HCM) has released an update. HUTCHMED and Innovent Biologics announce that China's NMPA has accepted their New Drug Appli...

New Hope in Advanced Endometrial Cancer Treatment

Standard Biotools enters strategic engagement with Bristol Myers for expanded use of Somascan platform

Hutchmed (China) Limited (HCM) has released an update. HUTCHMED (China) Limited is set to present new and updated data on its cancer treatment comp...

HUTCHMED to Unveil New Cancer Drug Data at AACR 2024

ProfoundBio will be acquired by Copenhagen's Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab's drug portfolio, including three ProfoundBio clinical stage ADC candidates for solid tumors.

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion

Hutchmed (China) Limited (HCM) has released an update. HUTCHMED (China) Limited has announced the vesting of non-performance based awards under its...

HUTCHMED Announces Key Managerial LTIP Vesting

Hutchmed (China) Limited (HCM) has released an update. HUTCHMED's partner Takeda has received a positive CHMP opinion for fruquintinib, a potential...

HUTCHMED Nears EU Approval for Cancer Drug

Despite the real estate industry crisis and other headwinds, the Chinese economy beats expectations to grow 5.3% in the first quarter, positioning it for future growth. Thus, top China stocks HUTCHMED (HCM), Autohome (ATHM), and Youdao (DAO) could be strong buys in May. Keep reading… Despite the deepening crisis in its property sector, China, the world's second-largest economy, reported a stronger-than-expected economic growth of 5.3% in the January-March quarter. Amid ongoing challenges, China is expected to support the economy with prudent monetary and proactive fiscal policies.
Given the industry's bright prospects, it could be wise to invest in fundamentally strong China stocks HUTCHMED (China) Limited (<a href="https://stocknews.com/stock/HCM/">HCM</a>), Autohome Inc. (<a href="https://stocknews.com/stock/ATHM/">ATHM</a>), and Youdao, Inc. (<a href="https://stocknews.com/stock/DAO/">DAO</a>) with solid buy potential in May.
Despite challenges in the real estate industry, import-export imbalances, and muted domestic demand, <a href="https://www.cnbc.com/2024/04/16/chinas-q1-gdp-grew-5point3percent-in-the-first-quarter-beating-expectations.html">China's GDP grew 5.3%</a> in the first quarter compared to the year ago, faster than the Reuters poll expectations of 4.6% growth and a revised fourth-quarter 1.2% expansion. Further, Beijing has set a 2024 <a href="https://www.cnbc.com/2024/03/05/china-gdp-target-2024.html#:~:text=BEIJING%20%E2%80%94%20China%20set%20a%20growth,for%20foreign%20investment%20in%20manufacturing.">growth target of around 5%</a> for the economy.
Zhiwei Zhang, president and chief economist at Pinpoint Asset Management, said, "Growth was driven in part by external demand, as export volume grew by 14% year on year".
Moreover, China's retail sales of consumer goods, a key indicator of the nation's consumption strength, <a href="http://english.scio.gov.cn/pressroom/2024-04/16/content_117129020.htm">surged 4.7% year-on-year</a> in the first quarter. Retail sales in the urban regions grew 4.6% year-over-year, while that in rural areas rose 5.2%. Online retail sales climbed 12.4 year-on-year, and sales of physical goods online increased by 11.6 %.
By opening its markets wider to foreign investors and promoting high-quality growth, China aims to be a critical force for the <a href="https://www.reuters.com/world/china/chinas-economy-will-provide-strong-driving-force-world-recovery-2024-03-28/">world's economic recovery this year</a>. The economy will harness tech innovation as a new point for economic growth and is open to forming associations with other countries.
Further, to combat ongoing headwinds, China's regulators will continue to support the economy with <a href="https://www.reuters.com/world/china/china-step-up-support-economy-flexibly-use-policy-tools-politburo-says-2024-04-30/">prudent monetary and proactive fiscal policies</a>, like interest rates and bank reserve requirement ratios (RRR), being flexible with policies in the world's second-biggest economy.
Considering the encouraging trends, let's delve into the fundamentals of the top three <a href="https://stocknews.com/category/china/">China</a> stocks, beginning with the third choice.
Stock #3: HUTCHMED (China) Limited (<a href="https://stocknews.com/stock/HCM/">HCM</a>)
Based in Hong Kong, HCM discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases internationally. It develops Savolitinib, and Fruquintinib. It also develops Surufatinib for treating pancreatic neuroendocrine tumor (NET) and Sovleplenib, which treat hematological cancers.
On April 26, HCM announced that its partner Takeda Pharmaceutical Co. Ltd. (<a href="https://stocknews.com/stock/TAK/">TAK</a>) received notification that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of fruquintinib for treating adult patients with previously treated metastatic colorectal cancer.
The positive opinion is based on results from FRESCO-2 Phase III clinical trial, and if approved in the European Union, fruquintinib will become the first novel targeted therapy for metastatic colorectal cancer.
On April 2, HCM and Innovent Biologics, Inc. announced that the NDA for the combination of fruquintinib and sintilimab for treating patients with advanced endometrial cancer with pMMR1 or non-MSI-H2 tumors was accepted and granted priority review by the China National Medical Products Administration (NMPA).
The combination of fruquintinib and sintilimab advances the potential to bring a new treatment option to endometrial cancer patients.
For the fiscal year that ended December 31, 2023, HCM's total revenue increased 96.5% year-over-year to $838 million, and its Oncology/Immunology consolidated revenue grew 222.6% year-over-year to $528.62 million.
In addition, <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> and EPS attributable to HUTCHMED came in at $100.78 million and $0.12 against net loss and loss per share of $360.83 million and $0.43 in the prior year's period, respectively. The company's total assets were $1.28 billion as of December 31, 2023, compared to $1.03 billion as of December 31, 2022.
Street expects HCM's revenue for the fiscal year 2025 to increase 22.7% year-over-year to $835.80 million, and the company's EPS for the same period is expected to be $0.30. Shares of HCM have surged 10.6% over the past month and 22.5% over the past year to close the last trading session at $18.51.
HCM's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
HCM has an A grade for Sentiment and a B for Value. It is ranked #13 out of 39 stocks in the B-rated <a href="https://stocknews.com/category/china/">China</a> industry.
In addition to the POWR Ratings we've stated above, we also have HCM ratings for Momentum, Quality, Stability, and Growth. Get all HCM ratings <a href="https://stocknews.com/stock/HCM/">here</a>.
Stock #2: Autohome Inc. (<a href="https://stocknews.com/stock/ATHM/">ATHM</a>)
Headquartered in Beijing, ATHM offers an online destination for automobile consumers in the People's Republic of China. It delivers interactive content and tools to automobile consumers through its websites, autohome.com.cn, che168.com, and ttpai.cn on PCs, mobile devices, mobile applications, and mini apps.
On December 12, 2023, ATHM's Board of Directors approved a cash dividend of $1.15 per ADS (or $0.2875 per ordinary share) to holders of ADSs and ordinary shares of record as of the close of business on December 29, 2023. The dividend was paid to holders of ordinary shares and ADS on March 27, 2024.
ATHM pays an annual dividend of $1.11, which translates to a yield of 4.33% at the current share price. Its four-year average dividend yield is 1.96%.
In terms of forward non-GAAP P/E, ATHM is trading at 11.09x, 17.8% lower than the industry average of 13.48x. Likewise, the stock's forward Price/Book multiple of 0.85 is 59% lower than the industry average of 2.08.
During the fourth quarter that ended December 31, 2023, ATHM's total net revenues increased marginally year-over-year to RMB 1.91 billion ($269.22 million), of which its online marketplace and others revenue rose 14.6% year-over-year to RMB 569.48 million ($78.62 million). Its gross profit grew 1.4% from the year-ago value to RMB 1.54 billion ($217.41 million)
Furthermore, adjusted net income attributable to Autohome and non-GAAP EPS came in at RMB 502.79 million ($70.82 million) and RMB 1.04 for the quarter, respectively.
Analysts expect ATHM's revenue and EPS for the fiscal year (ending December 2025) to increase 4.5% and 5.2% year-over-year to $1.08 billion and $2.43, respectively. Furthermore, the company has surpassed the consensus EPS and revenue estimates in all four trailing quarters, which is impressive.
ATHM's stock has gained 3.3% over the past three months to close the last trading session at $25.70.
ATHM's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
The stock has a B grade for Quality and Value. ATHM is ranked #8 among 39 stocks in the B-rated China industry.
<a href="https://stocknews.com/stock/ATHM/">Click here</a> to access ATHM's ratings for Growth, Stability, Momentum, and Sentiment.
Stock #1: Youdao, Inc. (<a href="https://stocknews.com/stock/DAO/">DAO</a>)
Based in Hangzhou, DAO is an internet technology company that offers online services in the fields of content, community, communication, and commerce. It operates in three segments: Learning Services; Smart Devices; and Online Marketing Services.
In terms of forward EV/Sales, DAO is trading at 0.67x, 42.8% lower than the industry average of 1.18x. Similarly, the stock's forward Price/Sales multiple of 0.49 is 42.7% lower than the industry average of 0.85.
DAO's trailing-12-month gross profit margin of 51.35% is 42.1% higher than the industry average of 36.12%. Likewise, the stock's trailing-12-month Asset Turnover Ratio of 2.73x is 177.6% higher than the industry average of 0.99x.
For the fourth quarter that ended December 31, 2023, DAO's total net revenues increased 1.8% year-over-year to $208.53 million, and its gross profit was $104.06 million. The company's income from operations grew 209.2% from the year-ago value to $10.74 million.
Also, non-GAAP net income from continuing operations attributable to ordinary shareholders of the company amounted to $9.76 million and $0.08 per ADS, increases of 122.6% and 132% year-over-year, respectively.
Street expects DAO's revenue for the first quarter (ended March 2024) to grow 12% year-over-year to $184.09 million. Also, the company's revenue is expected to increase 14.5% year-over-year to $858.33 million for the fiscal year 2024. In addition, DAO has surpassed the consensus EPS estimates in each of the trailing four quarters.
Over the past three months, DAO's stock has surged 7% to close the last trading session at $3.50.
DAO's POWR Ratings reflect its promising outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Sentiment. It also has a B grade for Growth and Value. Within the same industry, DAO is ranked #5 of 39 stocks.
<a href="https://stocknews.com/stock/DAO/">Click here</a> to access additional ratings of DAO for Momentum, Stability, and Quality.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
HCM shares were trading at $18.31 per share on Wednesday morning, down $0.20 (-1.08%). Year-to-date, HCM has gained 1.10%, versus a 5.85% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/hcm-athm-dao-tak-3-top-china-picks-for-may-with-strong-buy-signals/>3 Top China Picks for May With Strong Buy Signals</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Top China Picks for May With Strong Buy Signals

Hutchmed (China) Limited (HCM) has released an update. HUTCHMED (China) Limited has announced the appointment of Dr. Renu Bhatia as an Independent ...

HUTCHMED Welcomes New Board Member Expertise

ASND

ATHM

CHSYF

GMAB

INCY

IVBXF

ZLAB

Press Releases

HUTCHMED to Announce 2023 Final Results

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

Health Care

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

Management

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Indivior

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly and Co

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical

Teva Pharmaceutical Industries Limited American Depositary Shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

HUTCHMED (China) Stock (NASDAQ:HCM), Short Interest Report

People Also Watch